Analyst Price Target is $8.00
▲ +86.92% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Cingulate in the last 3 months. The average price target is $8.00, with a high forecast of $8.00 and a low forecast of $8.00. The average price target represents a 86.92% upside from the last price of $4.28.
Current Consensus is
Moderate Buy
The current consensus among 3 investment analysts is to moderate buy stock in Cingulate. This rating changed within the last month from a Hold consensus rating.
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Read More